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Immunoglobulin constant heavy G chain (IGHG) gene polymorphisms are associated with
atopy and can be determined by the serum Gm allotypes. We studied whether certain
polymorphisms are related to asthma severity and to the extent or intensity of allergic
sensitization in asthmatic subjects followed from childhood to young middle age.
Fifty-five subjects (28 males) with childhood asthma were all followed-up prospectively on
six occasions from a mean age of 9 to 35 years in a study including asthma severity scoring,
spirometry, skin prick, and specific serum IgE antibody testing. At the last visit, extended
lung function tests and a cold air challenge were performed, and IGHG gene polymorphisms
were identified by the alternative serum IgG subclass allotypes, employing ELISA and
double immunodiffusion.
The 19 subjects with the homozygous IGHG*bf/*bf genotype (originating from the IGHG3*b
and the IGHG1*f alleles, which are in strong linkage disequilibrium), showed significantly
higher asthma scores, lower airway function, and greater bronchodilator responses from
childhood to adulthood, and in middle age greater airway hyperresponsiveness, compared
to the subjects with the IGHG*bf/*ga or IGHG*ga/*ga genotypes. Among the subjects
sensitized to animal danders, those with the IGHG*bf/*bf genotype showed the highest
specific IgE levels.
In conclusion, IGHG gene polymorphisms were associated with the severity and outcome of
childhood asthma, and with the intensity of allergic sensitization.
& 2007 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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Asthma is a heterogeneous disorder differing widely in age
of onset, severity and outcome. Long-term follow-up studies
indicate that growing out of childhood asthma is the
exception rather than the rule, and that disease severity
in childhood is an important determinant of the outcome.1,2
We have previously reported the course of allergic sensitiza-
tion, clinical allergy, asthma severity, and airway function in
55 asthma subjects followed-up on six occasions from a
mean age of 9–35 years.3–7 We found that allergic sensitiza-
tion and reported allergies persisted in most subjects,
and that the extent of sensitization to perennial allergens
was associated with asthma severity and airway hyperre-
sponsiveness.5–7 However, this relationship was not straight-
forward, suggesting that additional modifying factors are
involved.
Gm allotypes (marker for IgG) refer to genetic variations
or polymorphisms at loci encoding for the constant heavy
chains of IgG (IGHG) and can be identified in serum.8–10 The
genetic codes for the heavy constant chains of the IgE and
IgG molecules are found on chromosome 14q32.3, with the
immunoglobulin heavy constant chain (IGH) genes in the
order 50m, d, g3, g1, a1, g2, g4, e, a2, 30.8 The IGHG genes
display Mendelian inheritance and are expressed randomly
by allelic exclusion.8 The alternative serum allotypes from
the g3, g1, or g2 genes have only minor amino acid
differences,11 but they are separate entities with distinct
immunochemical and functional characteristics, such as
fractionation rates, electrophoretic rates,12 half-life
times,13 and different maturation rate during childhood.14
Table 1 gives the nomenclature used in this paper for the
IGHG genes, alleles, and IgG subclass allotypes. Four subsets
of IGHG haplotypes (B cells) have been recognized based on
the alternative expressions from the IGHG3, IGHG1, and
IGHG2 genes, and can be identified via their expressed
subclass allotypes.15 The IGHG3 and IGHG1 genes are in
absolute linkage disequilibrium (LD): IGHG3*b is linked to
IGHG1*f, and IGHG3*g to IGHG1*a.
Previous studies have shown that some Gm allotypes are
associated with atopy in children,16 with allergic childhood
asthma,17 or with the acquisition of atopic allergy in
adults.18 Polymorphisms of IGHG are also known to influence
the susceptibility to several diseases, including bacterial
and viral infections,19,20 and it is of particular interest
that such polymorphisms appear to determine the strength
of the antibody response to various antigens.20–22 OurTable 1 Nomenclature and abbreviations used for the
IGHG genes, alleles, and IgG subclass allotypes.
Gene Alternative
alleles
Corresponding
IgG subclass
allotypes
IGHG3 (g3) *b, *g IgG3*b, IgG3*g
IGHG1 (g1) *f, *a IgG1*f, IgG1*a
IGHG2 (g2) *n, *-n IgG3*n, IgG3*-n
IGHG4 (g4) No allelic
variations
IgG4 (no subclass
allotypes)well-characterized asthma cohort gave us the opportunity
to investigate a possible relationship between certain Gm
allotypes and the extent or intensity of allergic sensitiza-
tion, and to study the association between Gm allotypes and
asthma severity from childhood to young middle age.
Methods
Subjects
The cohort included 55 subjects (28 males), all ethnic
Swedes, with doctor verified childhood asthma. They were
randomly recruited to a prospective follow-up asthma study
(at a mean age of 9 years) among patients attending a
pediatric outpatient asthma clinic. Three or more episodes
wheezing were used for the diagnosis of asthma in
accordance with Buffum.23 This was the generally used
asthma criterion in Sweden during the 1970s. The intentions
were to include asthmatic children who would be at least 7
years old at the planned first follow-up (to allow spirometry)
and to be half girls and half boys for gender comparison. All
subjects attended all six follow-up visits (visit 2–7) at mean
ages of 11.5, 13.6, 17.2, 24.3, 30.0, and 34.9 years. Detailed
information about the cohort and the findings at all follow-
ups has previously been reported.3–7
IGHG genotyping by the IgG alternative subclass
allotypes
The IgG subclass allotypes were determined by a sensitive
competitive indirect ELISA, measuring both the presence
and the serum concentrations of the IgG1*f, IgG1*a, IgG2*n,
and IgG3*b allotypes and IgG subclass levels, as described in
detail elsewhere.11 The sensitivity of the ELISA was
0.0008 g/l for IgG1*a, 0.0003 g/l for IgG1*f, 0.0006 g/l for
IgG2*n, and 0.0007 g/l for IgG3*b. The heterozygous
IgG2*n/-n genotype was detected by murine monoclonals
anti-G2m(n) 6016-10 clone SH-21 and anti-IgG2 HP 6014
(Sigma) in a double immunodiffusion assay. The IGHG alleles
and four IGHG haplotypes (B cell variants) were identified,
i.e. IGHG*bfn (B1), IGHG*bf-n (B2), IGHG*gan (B3), and
IGHG*ga-n (B4).
Asthma scores
History was taken using a standardized interview question-
naire. Asthma severity (a composite total asthma score, 0–6)
was estimated according to the frequency of wheezing
episodes (symptom score, 0–3) and the extent of medication
for asthma (medication score, 0–3), reported from the year
prior to the visit.4 Symptom score 1 denoted occasional
wheezing in connection with respiratory tract infections,
heavy exposure to allergens, and/or hard physical exercise.
Symptom score 2 denoted wheezing up to twice a week
and/or after ordinary physical exercise. Symptom score 3
implied wheezing more often than twice a week and/or
impairment of daily physical activities. Medication score 1
denoted occasional use of bronchodilator therapy for
symptomatic relief, and/or the use of inhaled sodium
cromoglycate or steroids for less than 3 months per year.
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Table 2 Frequencies of IGHG1 and IGHG2 alleles in the
55 subjects with childhood asthma and in a Caucasian
reference population (N ¼ 587; 157 blood donors and 430
healthy children).
Asthma cohort Reference
population
N % N %
IGHG1 alleles
*f 69 63 785 67
*a 41 37 389 33
IGHG2 alleles
*n 42 38 521 44
*-n 68 62 653 56
P.M. Gustafsson et al.268Medication scores 2 and 3, respectively, denoted the use of
bronchodilator therapy when needed and continuous use of
one (score 2) or two (score 3) preventive drugs for asthma
control.
Lung function tests
At visits 2–5, the forced expiratory volume in 1 s (FEV1) was
recorded using a wedge bellow spirometer before and after
inhalation of salbutamol from a jet nebulizer. In a study
performed in the same hospital during the 1970s of 85
healthy subjects aged 7–25 years, the mean (S.D.) increase
of FEV1 after salbutamol inhalation was 3.6 (2.3)% in males
and 3.5 (2.7)% in females24 All spirometric volumes were
converted to body temperature, pressure and saturated
air (BTPS) conditions, and expressed as percentages of
predicted values. Swedish normative data obtained in
children up to 18 years of age25 or from adults26,27 were
used where applicable.
At visits 6 and 7 FEV1, vital capacity (VC), and specific
airway resistance (sRaw) over five breaths were recorded at
rest, 5 and 10min after a cold dry air hyperventilation
challenge (CACh), and after salbutamol inhalation, in a body
plethysmograph.6,7 The maximum percentage fall in FEV1
after CACh was noted.
Peripheral airway function was assessed at visit 7 using a
He (helium) and SF6 (sulfur hexafluoride) single-breath
washout performed at rest, approximately 7min after CACh
and 15min after bronchodilator therapy.28 The concentra-
tion-normalized phase III slopes (SnIII) were computed. A
higher SnIII value indicates greater inhomogeneity of
ventilation distribution. In the present study only SF6 results
are reported.
Sensitization
At visit 7 total serum IgE concentrations and specific IgE
antibodies to the three most important perennial inhaled
allergens in Sweden, which are the danders of cat, dog, and
horse, to three pollens (birch, timothy, and mugwort), and
to two house dust mites (Dermatofagoides farinae, Derma-
tofagoides pteronyssinus) were determined using the
Phadebas CAP method (‘‘RAST’’; Pharmacia Diagnostics,
Uppsala, Sweden).7
Skin-prick tests (SPT) were performed using a panel of
standardized allergen extracts (ALK Copenhagen, Denmark).7
A weal with a mean diameter (half of the sum of the largest
diameter and its midpoint perpendicular) of more than 3mm
was regarded as positive. In the current analysis, the following
allergens were included: pollens (birch, hazel, grass, and
mugwort), furred animal danders (cat, dog, and horse), and
house dust mites (D. farinae and D. pteronyssinus).
Ethics
The ethics committee at the Central Hospital in Sko¨vde gave
initial approval to the study. During childhood and adoles-
cence the children and their parents gave their informed
consent before every follow-up. In adulthood informed
consent was received from all subjects.Data analysis
Likelihood ratio (LR) tests were used to test for the Hardy-
Weinberg equilibrium (HWE) and to compare diplotype
distributions between the asthma cohort and a Caucasian
reference population of 587 subjects.14,29 Haplotype frequen-
cies for LD estimation were calculated using the Expectation-
Maximization (EM) algorithm. Repeated measurements ANOVA
was used to investigate genetic effects on bronchodilator
response and baseline % predicted FEV1 over all follow-up
stations, with the allele count (0, 1, 2) as covariate, while the
relationship between the mean total score taken over all
follow-up visits and the genotype was tested with linear
regression. At the last visit Spearman rank correlation tests
were used to assess the relationship to allele counts.
Proportions were compared with the Yates corrected w2-test.
Other two group comparisons were made using the
Mann–Whitney U-test. A p-value o0.05 was accepted as
statistically significant. No corrections for multiple testing
were performed since genotypes are correlated with each
other due to LD and because the phenotypes assessed by
different measures and aspects of asthma are also highly
correlated. A Bonferroni correction would therefore be overly
conservative. Statistica 6.0 (StatSoft, Tulsa, OK, USA) was
used for the statistical analyses.Results
Genotype and allele distribution
Six IGHG genotypes were identified with respect to the
alternative alleles for IGHG3, IGHG1, and IGHG2. There was
a slight deviation from the HWE in the reference population
(p ¼ 0.004) with respect to IGHG2 with fewer homozygotes
(IGHG2*n/*n 10.9%) than expected (22%).
The allele frequencies were similar in the asthma group
and the reference population (Table 2). The three genes
were all in LD. IGHG3 and IGHG1 were in absolute LD
(D0 ¼ r2 ¼ 1), where IGHG3*b was associated with IGHG1*f.
IGHG1 and IGHG2 were also in strong LD (D0 ¼ 0.87,
r2 ¼ 0.30), where IGHG*bf was associated with IGHG*n.
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Correlation analysis showed statistically significant associa-
tions between the number of IGHG*bf alleles and several
aspects of asthma severity: total asthma scores, bronchial
hyperresponsiveness to CACh, baseline airway resistance,
and baseline ventilation inhomogeneity (SF6 SnIII), all
assessed at the last follow-up (Table 3). The relationship
between FEV1/VC (%) and IGHG*bf alleles just failed to
reach significance. There were no significant correlations
between asthma scores or lung function variables and the
number of IGHG2*n alleles (data not given). Total serum-IgE
levels or the extent of sensitization, as determined by the
number of positive RASTs or SPTs, did not correlate with the
number of IGHG*bf alleles (Table 3) or IGHG*n alleles (data
not shown).Asthma course
At visit 7, 5 subjects had a total asthma score of 5 or 6, 10
subjects scored 3 or 4, and 28 had a score of 1 or 2. Asthma
was in remission in 12 subjects at visit 7 (21%; 9 males and 3
females) who had a total asthma score of 0. Eight subjects
were taking inhaled corticosteroids regularly and four of
these also used long-acting beta2 agonists daily.
7
Over the six follow-up stations as a whole, total asthma
scores were significantly associated with the IGHG*bf allele
(p ¼ 0.001; Figure 1). The IGHG*bf allele was also asso-
ciated with a greater bronchodilator response (p ¼ 0.005)
and a lower baseline percentage of predicted FEV1
(p ¼ 0.024). Total asthma scores or lung function measure-Table 3 Total asthma scores, airway function, sensitization, a
subjects with respect to IGHG3 and IGHG1 genotypes.
Variables IGHG3 and IGHG1 genoty
*bf/*bf (N ¼ 19) *bf/
Total asthma score, median (range) 3 (0–6) 2 (0
Airway function, mean (SD)
Max fall in FEV1 after CACh (%) 21.4 (17.4) 12.0
Baseline FEV1 (% pred) 89.6 (12.0) 92.2
Baseline FEV1 /VC (%) 73.6 (7.4) 74.9
Baseline sRaw (kPa s) 1.02 (0.58) 0.77
Baseline SF6 SnIII (l
1) 0.255 (0.092) 0.19
Overall sensitization, median (range)
RAST, no. positive tests 4 (0–7) 2 (0
SPT, no. of positive tests 5 (1–8) 4 (0
Sensitization to three furred animals tested, median (range)
RAST, no. positive tests 3 (0–3) 1 (0
SPT, no. of positive tests 3 (0–3) 2 (0
Total S-IgE (kU/l), median (range) 129 (21–4125) 84 (
The statistical analysis encompasses correlation tests (Rs; Spearman R
alleles (2, 1, or 0). CACh ¼ cold air hyperventilation challenge, sRa
slope for SF6. For remaining abbreviations, see Methods.ments were not significantly associated with the IGHG2
polymorphisms (data not shown).Asthma severity and sensitization to animal danders
At visit 7, the extent of sensitization, as measured by a
positive RAST, to any of the three furred animal danders
studied, did not differ significantly between the 19 IGHG*bf
homozygotes and the 36 remainders (14/19 vs. 22/36;
p ¼ 0.5; Figure 2). All five subject with severe asthma (total
asthma scores 5 or 6) were, however, homozygous for the
IGHG*bf/*bf genotype and sensitized to at least one animal
dander, whilst none of the similarly sensitized subjects with
the IGHG*bf/*ga or IGHG*ga/*ga genotypes had severe
asthma (p ¼ 0.012; Figure 2).
Subjects with the homozygous IGHG*bf/*bf genotype who
were sensitized to any of the three animal danders had
higher median serum concentrations of IgE antibodies to
these allergens than the similarly sensitized subjects with
the IGHG*bf/*ga or IGHG*ga/*ga genotypes: for cat 9.3 kU/l
vs. 2.6 kU/l (p ¼ 0.005; N ¼ 11 and N ¼ 21, respectively);
for dog 11.9 kU/l vs. 3.0 kU/l (p ¼ 0.035; N ¼ 13 and N ¼ 16,
respectively); and for horse 4.1 kU/l vs. 2.4 kU/l (p ¼ 0.170;
N ¼ 13 and N ¼ 9, respectively).Asthma course, gender, and IGHG genotypes
Total asthma scores decreased markedly (median reduction
2 score units from visit 2 to visit 7; p ¼ 0.018; Figure 3) over
the six follow-up visits among the 10 males who were
homozygous for the IGHG*bf/*bf genotype and decreased
slightly also among the 18 males with the IGHG*bf/*ga ornd total serum-IgE at visit 7 (mean age 34.9 years) in all 55
pes Statistics
*ga (N ¼ 31) *ga/*ga (N ¼ 5)
–4) 1 (0–3) Rs ¼ 0.373, p ¼ 0.005
(10.5) 6.6 (5.6) Rs ¼ 0.357, p ¼ 0.007
(11.4) 100.6 (3.6) Rs ¼ 0.235, p ¼ 0.085
(7.0) 81.9 (3.5) Rs ¼ 0.262, p ¼ 0.053
(0.41) 0.35 (0.11) Rs ¼ 0.376, p ¼ 0.005
4 (0.078) 0.178 (0.102) Rs ¼ 0.323, p ¼ 0.016
–5) 5 (0–7) Rs ¼ 0.220, p ¼ 0.107
–7) 5 (1–8) Rs ¼ 0.184, p ¼ 0.178
–3) 3 (0–3) Rs ¼ 0.187, p ¼ 0.173
–3) 3 (0–3) Rs ¼ 0.196, p ¼ 0.152
7–860) 151 (15–378) Rs ¼ 0.136, p ¼ 0.321
ho) between the measured variables and the number of IGHG*bf
w ¼ specific airway resistance, SF6 SnIII ¼ normalized phase III
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Figure 1 Mean total asthma scores, mean percentage increase
in FEV1 after bronchodilation (reversibility %), and mean
baseline FEV1 (% predicted) in all 55 subjects over visits 2–7
with respect to IGHG genotypes: IGHG*bf/*bf (N ¼ 19) (black
filled circles), IGHG*bf/*ga (N ¼ 31) (gray filled circles), and
IGHG*ga/*ga (N ¼ 5) (open circles). (p-values refer to compar-
isons between the three groups over the follow-up as a whole.)
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Figure 2 Asthma severity (total asthma scores) distribution at
visit 7 in relation to the extent (0–3) of sensitization (limit for
positive RAST40.70 kU/l) to three furred animals danders (cat,
dog, and horse) among the 19 subjects homozygous for the
IGHG*bf/*bf genotype, and among the remainders (31 IGHG*bf/*ga
and 5 IGHG*ga/*ga subjects).
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Figure 3 Mean total asthma scores over visits 2 to 7 for male
and female subjects with the IGHG*bf/*bf genotype (circles;
N ¼ 19), and for male and female subjects with the IGHG*bf/*ga
(N ¼ 31) or the IGHG*ga/*ga genotypes (N ¼ 5) (triangles).
P.M. Gustafsson et al.270IGHG*ga/*ga genotypes (median reduction 1 score unit;
p ¼ 0.028). By contrast, total asthma scores tended to
increase among the females who were homozygous for the
IGHG*bf/*bf genotype (median increase 1 score unit;
p ¼ 0.063), and did not change among the female remain-
ders. The difference in score change between males and
females was highly significant among those with the
IGHG*bf/*bf genotype (po0.001), but not among the
remainders (p ¼ 0.091).Discussion
The present study demonstrates a clear association between
the IGHG*bf allele and asthma severity in young middle age,
judged both clinically and with several tests of airway
function. Similar results were recorded all through the
follow-up period from childhood. Furthermore, the IGHG*bf
allele was related to the intensity of sensitization to
perennial allergens. The IGHG*bf alleles were, however,
not overrepresented in the cohort compared to a reference
population, indicating that they are not linked to the risk of
acquiring asthma.
To our knowledge, there are no previously published
studies on Gm allotypes and the course and outcome of
childhood asthma. At the last follow-up, the highest asthma
scores, the most pronounced airway hyperresponsiveness,
and the lowest baseline central (sRaw) or peripheral (SF6
SnIII) airway function were found among the subjects with
the homozygous IGHG*bf/*bf genotype. The subjects lacking
these alleles had the lowest asthma scores, were least
reactive to cold air challenge and had the best baseline
airway function, whilst the heterozygotes showed inter-
mediate results. Over the whole 26-year follow-up period,
the IGHG*bf/*bf genotype was associated with the most
severe asthma judged both from clinical scores and lung
function findings. The extent of allergic sensitization or
total serum IgE did not show a clear association with the
IGHG*bf alleles. Interestingly, severe asthma was found only
in subjects with the IGHG*bf/*bf genotype who were
sensitized to at least one animal dander. Furthermore, the
intensity of sensitization to furred animal allergens was
higher in the sensitized subjects who had the IGHG*bf/*bf
genotype than in the sensitized remainders.
It is well known that there are differences in asthma
prevalence and airway behavior between males and females
over lifetime.2,30 In the present study, the difference in
total asthma scores between the IGHG*bf/*bf genotype and
the remainders was seen in both sexes over the whole
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asthma severity among the males vs. the females in this
cohort6,7 was most pronounced among those with the
IGHG*bf/*bf genotype, where the males had the largest
room for improvement.
The study included relatively few patients, but they all
attended all follow-up visits over a period of 26 years and
their asthma was carefully characterized with respect to
clinical, allergological, and physiological features. The
follow-up covered a period of life when major changes
occur in terms of growth, maturation, and living conditions.
Nevertheless, distinct differences in clinical asthma severity
and lung function were found between the different IGHG3/
IGHG1 genotypes over the whole follow-up period. Further-
more, our finding of an allele dose–response with respect to
airway hyperresponsiveness and lung function is character-
istic for a gene influence. However, if the initial difference
in asthma severity between the genotypes had occurred by
chance, not involving any causal relationship, then it
would probably persist over the follow-up. There is there-
fore a need to assess these associations in other asthma
populations.
There was no significant relationship between the number
of IGHG2*n alleles and asthma severity or allergic sensitiza-
tion. In a previous study in childhood asthma, an association
was found between the IGHG*bfn/*bfn genotype and allergic
asthma.17 In another study, an overrepresentation of the
IGHG*bfn allele was found in laboratory technicians devel-
oping allergy to furred animals.18 A recent study of subjects
participating in the International Study of Asthma and
Allergy in Children (ISAAC) showed an association between
the IGHG*bfn allele and the occurrence of allergic sensitiza-
tion, family history of atopy, and clinical allergy.16 In the
present study there were only six subjects with the
IGHG2*n/*n genotype, and all had the IGHG*bfn/*bfn
genotype (Table 2). As expected in a pediatric asthma
population, the great majority of the subjects in the present
asthma cohort (90%) were sensitized to any allergen.
Therefore, the influence of any polymorphisms on adopting
allergic sensitization could not be assessed.
The study patients were recruited randomly among
Swedish asthmatic school children born during the 1960s
and referred from primary care physicians to a pediatric
outpatient asthma clinic in a general hospital in the mid-
1970s. This was prior to the ‘‘asthma epidemic’’, which is
generally regarded to be the result of a modern Western life
style. As asthma is thought to result from the interaction
between several genes and environment,31 it can be
speculated that the gene interaction with the altered
environment and life style of today promotes asthma
development also in other genotypes than those associated
with acquiring asthma in the 1960s. It therefore remains to
be seen if asthma severity and long-term asthma outcome in
school children born more recently and also in those with
non-Caucasian origin are similarly associated with IGHG
polymorphisms.
Over the follow-up period, bronchodilator response was
greater in the 19 subjects with the homozygous IGHG*bf/*bf
genotype than in the remaining 36 subjects, indicating that
these alleles are related to bronchial hyperresponsiveness.
At the last follow-up visit, tests of large and small airway
function showed that the whole airway tree was moreseverely affected in the subjects with homozygous
IGHG*bf/*bf genotype. A clear relationship has previously
been shown between the degree of airway responsiveness in
asthma and the intensity of airway inflammation,32,33 giving
indirect evidence of greater airway inflammation among the
subjects with IGHG*bf/*bf genotype during the whole
follow-up period. The greater intensity of allergic sensitiza-
tion to perennial allergens in this subgroup lends support to
this notion.
To conclude, the present study shows a clear and
consistent association between IGHG gene polymorphisms,
identified by the alternative serum IgG subclass allotypes,
and asthma severity from childhood to young middle age,
and that these polymorphisms are related to the intensity of
allergic sensitization to relevant perennial allergens.
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